AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

NCT06591520 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: AK112, Gemcitabine, Cisplatin
DRUG: Durvalumab, Gemcitabine, Cisplatin

Sponsor

Akeso